{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T02:36:36Z","timestamp":1788230196414,"version":"build-2803163510"},"reference-count":47,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:00:00Z","timestamp":1672876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Gr\u00fcnenthal Group (Germany)","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["Cancers"],"abstract":"<jats:p>Introduction: Chemotherapy-induced peripheral neuropathy (CIPN) is often painful and can arise during or after the end of oncological treatments. They are mostly induced by platinum salts, taxanes, and immunotherapies. Their incidence is estimated between 19 and 85%. They can require a chemotherapy dose reduction or early termination. The European Society for Medical Oncology (ESMO) recommends high-concentration capsaicin patch (HCCP) in second line for the treatment of painful CIPN. This treatment induces a significative pain relief but only shown by low-powered studies. The objective of this study was to evaluate efficacy and tolerability of HCCP applications in CIPN. Methods: This monocentric observational retrospective real-world-data study of the CERCAN cohort took place in the Western Cancer Institute\u2019s Anaesthesiology and Pain Department at Angers, France. Independent pain physicians completed the CGIC (Clinician Global Impression of Change) for each patient who benefited from HCCP applications for painful CIPN starting from 1 January 2014 to 22 December 2021, based on the collected data after every patch application. Results: A total of 57 patients (80.7% women) was treated with HCCP for painful CIPN, and 184 applications were realized, consisting of 296 sessions. CGIC found an important or complete pain relief for 61 applications (33.2%, corresponding to 43.9% patients). We found less efficacy for platinum-salts-induced CIPN compared to others (p = 0.0238). The efficacy was significatively higher for repeated applications when HCCP was used in second line compared to third line (p = 0.018). The efficacy of HCCP was significatively higher starting the third application (p = 0.0334). HCCPs were mainly responsible for local adverse events found in 66.6% patients (65.1% burning or painful sensation, 21.1% erythema). Conclusion: HCCP applications in painful CIPN induce an important pain relief with a global satisfying tolerability.<\/jats:p>","DOI":"10.3390\/cancers15020349","type":"journal-article","created":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T04:51:31Z","timestamp":1672894291000},"page":"349","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Evaluation of 8% Capsaicin Patches in Chemotherapy-Induced Peripheral Neuropathy: A Retrospective Study in a Comprehensive Cancer Center"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5940-4099","authenticated-orcid":false,"given":"Florent","family":"Bienfait","sequence":"first","affiliation":[{"name":"Anaesthesiology and Pain Department, Institut de Canc\u00e9rologie de l\u2019Ouest, 49100 Angers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Julienne","sequence":"additional","affiliation":[{"name":"Anaesthesiology and Pain Department, Institut de Canc\u00e9rologie de l\u2019Ouest, 49100 Angers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Jubier-Hamon","sequence":"additional","affiliation":[{"name":"Anaesthesiology and Pain Department, Institut de Canc\u00e9rologie de l\u2019Ouest, 49100 Angers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1404-0292","authenticated-orcid":false,"given":"Valerie","family":"Seegers","sequence":"additional","affiliation":[{"name":"Biometrics Department, Institut de Canc\u00e9rologie de l\u2019Ouest, 49100 Angers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Delorme","sequence":"additional","affiliation":[{"name":"Anaesthesiology and Pain Department, Institut de Canc\u00e9rologie de l\u2019Ouest, 49100 Angers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Jaoul","sequence":"additional","affiliation":[{"name":"Anaesthesiology and Pain Department, Institut de Canc\u00e9rologie de l\u2019Ouest, 49100 Angers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves-Marie","family":"Pluchon","sequence":"additional","affiliation":[{"name":"Pain Management Consultation Center, Centre Hospitalier D\u00e9partemental Vend\u00e9e, 85925 La Roche-sur-Yon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Lebrec","sequence":"additional","affiliation":[{"name":"Anaesthesiology and Pain Department, Institut de Canc\u00e9rologie de l\u2019Ouest, 49100 Angers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1777-2130","authenticated-orcid":false,"given":"Denis","family":"Dupoiron","sequence":"additional","affiliation":[{"name":"Anaesthesiology and Pain Department, Institut de Canc\u00e9rologie de l\u2019Ouest, 49100 Angers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,5]]},"reference":[{"key":"ref_1","first-page":"16","article-title":"Global Cancer Incidence and Mortality Rates and Trends-An Update","volume":"25","author":"Torre","year":"2016","journal-title":"Cancer Epidemiol. Biomark. Prev. Publ. Am. Assoc. Cancer Res. Cosponsored. Am. Soc. Prev. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1200\/JCO.2013.52.4629","article-title":"Pain in Cancer Survivors","volume":"32","author":"Glare","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1212\/01.wnl.0000282763.29778.59","article-title":"Neuropathic pain: Redefinition and a grading system for clinical and research purposes","volume":"70","author":"Treede","year":"2007","journal-title":"Neurology"},{"key":"ref_4","first-page":"419","article-title":"Chemotherapy-induced peripheral neurotoxicity: A critical analysis","volume":"63","author":"Park","year":"2013","journal-title":"CA Cancer J. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature","volume":"73","author":"Cuzzubbo","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","article-title":"Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis","volume":"155","author":"Seretny","year":"2014","journal-title":"Pain"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"iv45","DOI":"10.1093\/neuonc\/nos203","article-title":"Peripheral neuropathies from chemotherapeutics and targeted agents: Diagnosis, treatment, and prevention","volume":"14","author":"Grisold","year":"2012","journal-title":"Neuro-Oncology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/annonc\/mdh348","article-title":"Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy","volume":"15","author":"Cavaletti","year":"2004","journal-title":"Ann. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.neulet.2014.10.014","article-title":"Chemotherapy-induced peripheral neuropathy: What do we know about mechanisms?","volume":"596","author":"Carozzi","year":"2015","journal-title":"Neurosci. Lett."},{"key":"ref_10","first-page":"4223","article-title":"Chemotherapy-induced peripheral neuropathy (CIPN): Current therapies and topical treatment option with high-concentration capsaicin","volume":"29","author":"Diel","year":"2021","journal-title":"Support Care Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"113141","DOI":"10.1016\/j.expneurol.2019.113141","article-title":"Pathogenesis of platinum-induced peripheral neurotoxicity: Insights from preclinical studies","volume":"325","author":"Calls","year":"2020","journal-title":"Exp. Neurol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2008.07558.x","article-title":"Therapy of chemotherapy-induced peripheral neuropathy","volume":"145","author":"Kaley","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Kneis, S., Wehrle, A., Dalin, D., Wiesmeier, I.K., Lambeck, J., Gollhofer, A., Bertz, H., and Maurer, C. (2020). A new approach to characterize postural deficits in chemotherapy-induced peripheral neuropathy and to analyze postural adaptions after an exercise intervention. BMC Neurol., 20.","DOI":"10.1186\/s12883-019-1589-7"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1186\/2193-1801-3-366","article-title":"Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: A single-center experience","volume":"3","author":"Bhatnagar","year":"2014","journal-title":"Springerplus"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1200\/JCO.2005.04.7779","article-title":"Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With Bortezomib","volume":"24","author":"Richardson","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ygyno.2018.03.052","article-title":"Course of chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer patients: A longitudinal study","volume":"149","author":"Bonhof","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2217\/pmt-2018-0020","article-title":"An updated understanding of the mechanisms involved in chemotherapy-induced neuropathy","volume":"8","author":"Hou","year":"2018","journal-title":"Pain Manag."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1002\/cncr.31248","article-title":"Beyond symptomatic relief for chemotherapy-induced peripheral neuropathy: Targeting the source","volume":"124","author":"Ma","year":"2018","journal-title":"Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/ana.24951","article-title":"Chemotherapy-induced peripheral neuropathy: A current review","volume":"81","author":"Staff","year":"2017","journal-title":"Ann. Neurol."},{"key":"ref_20","first-page":"913848","article-title":"Healthcare Costs and Workloss Burden of Patients with Chemotherapy-Associated Peripheral Neuropathy in Breast, Ovarian, Head and Neck, and Nonsmall Cell Lung Cancer","volume":"2012","author":"Pike","year":"2012","journal-title":"Chemother. Res. Pr."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.annonc.2020.07.003","article-title":"Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up","volume":"31","author":"Jordan","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2013.2813","article-title":"Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: A randomized clinical trial","volume":"309","author":"Smith","year":"2013","journal-title":"JAMA"},{"key":"ref_23","unstructured":"EMEA (2022, August 10). Qutenza-Epar-Public-Assessment-Report_en.pdf [Internet]. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/qutenza-epar-public-assessment-report_en.pdf."},{"key":"ref_24","unstructured":"EMEA (2022, August 10). Qutenza-Epar-Assessment-Report-Variation_en.pdf [Internet]. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/qutenza-h\/c-909-ii-0039-epar-assessment-report-variation_en.pdf."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Mankowski, C., Poole, C.D., Ernault, E., Thomas, R., Berni, E., Currie, C.J., Treadwell, C., Calvo, J.I., Plastira, C., and Zafeiropoulou, E. (2017). Effectiveness of the capsaicin 8% patch in the management of peripheral neuropathic pain in European clinical practice: The ASCEND study. BMC Neurol., 17.","DOI":"10.1186\/s12883-017-0836-z"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","article-title":"Pharmacotherapy for neuropathic pain in adults: A systematic review and meta-analysis","volume":"14","author":"Finnerup","year":"2015","journal-title":"Lancet Neurol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ejphar.2004.07.037","article-title":"The role of the vanilloid (capsaicin) receptor (TRPV1) in physiology and pathology","volume":"500","author":"Nagy","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"ref_28","first-page":"CD007393","article-title":"Topical capsaicin (high concentration) for chronic neuropathic pain in adults","volume":"2021","author":"Derry","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jpain.2016.09.008","article-title":"Capsaicin 8% Patch in Painful Diabetic Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Study","volume":"18","author":"Simpson","year":"2016","journal-title":"J. Pain"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/FTD.0b013e3181a8b200","article-title":"Pharmacokinetic Analysis of Capsaicin After Topical Administration of a High-Concentration Capsaicin Patch to Patients With Peripheral Neuropathic Pain","volume":"31","author":"Babbar","year":"2009","journal-title":"Ther. Drug Monit."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"i5309","DOI":"10.1136\/bmj.i5309","article-title":"Revisiting the drug interaction between tamoxifen and SSRI antidepressants","volume":"354","author":"Juurlink","year":"2016","journal-title":"BMJ"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.2147\/JPR.S213912","article-title":"Rational treatment of chemotherapy-induced peripheral neuropathy with capsaicin 8% patch: From pain relief towards disease modification","volume":"12","author":"Anand","year":"2019","journal-title":"J. Pain Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s12032-017-1015-1","article-title":"High-dose 8% capsaicin patch in treatment of chemotherapy-induced peripheral neuropathy: Single-center experience","volume":"34","author":"Krzyzewski","year":"2017","journal-title":"Med. Oncol. Northwood. Lond. Engl."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e14031","DOI":"10.1200\/JCO.2016.34.15_suppl.e14031","article-title":"Improvement of chemotherapy induced neuropathy (CIN) in cancer patients using capsaicin 8% patch","volume":"34","author":"Berard","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1200\/jco.2016.34.26_suppl.208","article-title":"Investigating high-concentration 8% capsaicin patch in chronic cancer-treatment related peripheral neuropathic pain","volume":"34","author":"Ramnarine","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2147\/JPR.S341378","article-title":"Peripheral Neuropathic Pain Following Breast Cancer: Effectiveness and Tolerability of High-Concentration Capsaicin Patch","volume":"15","author":"Dupoiron","year":"2022","journal-title":"J. Pain Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3389\/fncel.2016.00079","article-title":"Long-Term Activation of Group I Metabotropic Glutamate Receptors Increases Functional TRPV1-Expressing Neurons in Mouse Dorsal Root Ganglia","volume":"10","author":"Masuoka","year":"2016","journal-title":"Front. Cell. Neurosci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1111\/bph.15086","article-title":"Taxane-induced neurotoxicity: Pathophysiology and therapeutic perspectives","volume":"177","author":"Passos","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"ref_39","first-page":"2324","article-title":"Progressive Response to Repeat Application of Capsaicin 179 mg (8% w\/w) Cutaneous Patch in Peripheral Neuropathic Pain: Comprehensive New Analysis and Clinical Implications","volume":"22","author":"Freynhagen","year":"2021","journal-title":"Pain Med. Malden. Mass."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1002\/ejp.1180","article-title":"Pain-relieving effectiveness, quality of life and tolerability of repeated capsaicin 8% patch treatment of peripheral neuropathic pain in Scandinavian clinical practice","volume":"22","author":"Hansson","year":"2018","journal-title":"Eur. J. Pain Lond. Engl."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"198","DOI":"10.2174\/1389200221999201116143701","article-title":"Topical Capsaicin for the Treatment of Neuropathic Pain","volume":"22","author":"Sultana","year":"2021","journal-title":"Curr. Drug Metab."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.2147\/JPR.S190231","article-title":"Acetyl-L-carnitine in painful peripheral neuropathy: A systematic review","volume":"12","author":"Galosi","year":"2019","journal-title":"J. Pain Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1200\/JCO.2012.44.8738","article-title":"Randomized Double-Blind Placebo-Controlled Trial of Acetyl-L-Carnitine for the Prevention of Taxane-Induced Neuropathy in Women Undergoing Adjuvant Breast Cancer Therapy","volume":"31","author":"Hershman","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1200\/JCO.20.01399","article-title":"Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update","volume":"38","author":"Loprinzi","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.annonc.2019.09.006","article-title":"Multicenter randomized controlled trial to evaluate the efficacy and tolerability of frozen gloves for the prevention of chemotherapy-induced peripheral neuropathy","volume":"31","author":"Beijers","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_46","first-page":"2769","article-title":"Cancer treatment-related neuropathic pain: Proof of concept study with menthol\u2014A TRPM8 agonist","volume":"23","author":"Fallon","year":"2015","journal-title":"Support Care Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/NCC.0000000000000693","article-title":"A Randomized Controlled Trial to Assess the Effectiveness of Muscle Strengthening and Balancing Exercises on Chemotherapy-Induced Peripheral Neuropathic Pain and Quality of Life Among Cancer Patients","volume":"43","author":"Dhawan","year":"2020","journal-title":"Cancer Nurs."}],"updated-by":[{"DOI":"10.3390\/cancers15143613","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:00:00Z","timestamp":1672876800000}}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/2\/349\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T22:27:18Z","timestamp":1754260038000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/2\/349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,5]]},"references-count":47,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["cancers15020349"],"URL":"https:\/\/doi.org\/10.3390\/cancers15020349","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,5]]}}}